Translational Challenges for Hepatocyte-Directed Gene Transfer by Stephanie C. Gordts et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Translational Challenges for  
Hepatocyte-Directed Gene Transfer 
Stephanie C. Gordts, Eline Van Craeyveld, Frank Jacobs and Bart De Geest 
Center for Molecular and Vascular Biology, University of Leuven, Leuven, 
Belgium 
1. Introduction 
The liver is a central organ in many metabolic processes. Multiple inherited metabolic 
disorders have their origin in this organ. Therefore, hepatocytes are a key target for gene 
therapy directed at correction of inborn errors of metabolism and of hemophilia. Inborn 
errors of metabolism lead to accumulation of toxic products in hepatocytes and extensive 
hepatotoxicity, as observed in disorders like 1-antitrypsin deficiency, type I tyrosinemia, or 
Wilson disease1. In other metabolic disorders, such as in Crigler-Najjar syndrome type I, 
ornithine transcarbamylase deficiency, familial hypercholesterolemia, and hemophilia A 
and B, manifestations are primarily extrahepatic1. In addition, the liver is a target for gene 
therapy of acquired diseases such as liver cancer and hepatitis2, 3.  
Insights into the determinants of gene transfer efficiency to hepatocytes are therefore 
required to evaluate the potential of gene therapy for inborn errors of metabolism and for 
acquired liver diseases. These determinants include innate and adaptive immune responses, 
cellular and biochemical determinants of hepatocyte transduction such as ligand receptor 
interactions, and anatomical and histological factors. Here we will first focus on the role of 
liver sinusoidal cells and sinusoidal fenestrae as determinants of the efficiency in 
hepatocyte-directed gene transfer. Uptake of gene transfer vectors by Kupffer cells and liver 
sinusoidal endothelial cells limits hepatocyte transduction4-11. However, the presence of 
fenestrae in liver sinusoidal endothelial cells provides a direct access to the space of Disse 
and microvillous surface of hepatocytes and may allow transcellular migration of vectors. In 
the following paragraphs, we provide substantial evidence that the interplay between these 
opposing forces, i.e. uptake by non-parenchymal liver cells and transcellular migration 
through fenestrae, is a critical determinant of gene transfer efficiency into hepatocytes.  
Before discussing the different parameters that influence the efficiency of hepatocyte-
directed gene transfer, it is important to point out that the process of gene transfer to 
parenchymal liver cells using replication-defective virus-derived vectors or non-viral 
vectors is fundamentally different from infection of hepatocytes by hepatotropic viruses. 
After successful infection, viruses replicate, leading to an exponential local increase of viral 
load. Consequently, a very small inoculum may be sufficient to induce hepatitis. In contrast, 
the number of transgenes carried by viral gene transfer vectors that pass through fenestrae 
cannot be amplified in hepatocytes since these vectors are replication defective. The number 
of vector particles that pass through fenestrae and are subsequently taken up by hepatocytes 
is therefore a critical determinant of transgene DNA copy number in these cells and of 
transgene expression levels.  
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2. Liver anatomy and histology 
The liver is the largest internal organ of the human body, weighs about 1.5 kg, and is located 
in the upper right quadrant of the abdomen. The liver is highly vascularised and the total 
blood flow through the liver can reach up to 25% of the cardiac output. Approximately 75% 
of the blood that enters the liver derives from the portal vein that carries oxygen-poor blood. 
Oxygenated blood entering the liver via the hepatic artery constitutes the remaining 25% of 
blood supply. The portal vein, the hepatic artery, lymphatic vessels, nerves, and bile ducts 
enter the liver at the hilus. From the hilus, continuous branching of the hepatic artery and 
portal vein results in an intricate network of intertwining capillaries, called sinusoids. 
Histologically, the liver is divided into lobuli, hexagonal functional units formed by 
hepatocytes and sinusoids surrounding a central vein. Neighbouring lobules are 
surrounded by portal triads, consisting of branches of the bile duct, the portal vein, and the 
hepatic artery.  
A human liver comprises 4.5 x 1011 cells12, 13. A murine liver contains approximately 1.6 x 108 
cells12 whereas a rabbit liver counts about 1.5 x 1010 cells. These data allow to calculate the 
ratio of transgene copies contained in a given vector dose versus the number of hepatocytes, 
which can be calculated as 66% of the total number of liver cells. Empirical determination of 
the transgene DNA copy number per hepatocyte is hampered by the fact that copy numbers 
per diploid genome do not accurately reflect transgene DNA copy numbers per hepatocyte. 
Indeed, hepatocytes are frequently tetraploid or even octoploid and may also have a 
binuclear nucleus. 
3. Liver sinusoidal cells 
Sinusoidal cells constitute approximately 33% of the number of resident liver cells whereas 
parenchymal liver cells or hepatocytes comprise the remaining cells14-16. Sinusoidal cells are 
a compilation of endothelial cells, Kupffer cells (resident liver macrophages), fat-storing 
cells (also called stellate cells or Ito cells), and pit cells (natural killer cells). Liver sinusoidal 
endothelial cells comprise 70%, Kupffer cells 20%, stellate cells 10%, and pit cells less than 
1% of the number of sinusoidal cells14, 16, 17. In the context of hepatocyte-directed gene 
transfer, we focus here on the role of Kupffer cells and liver sinusoidal endothelial cells that 
constitute together the reticulo-endothelial cells of the liver. Kupffer cells account for 80% to 
90% of resident macrophages in the entire body18. They have a diameter of 10-15 m 
whereas liver sinusoidal endothelial cells are smaller with a diameter of 7-9 m14. Sinusoidal 
endothelial cells are scavenger cells that are able to internalize particles up to 0.23 µm under 
physiologic conditions in vivo19. Larger particles are taken up by Kupffer cells19. Since most 
gene transfer vectors have a diameter below 0.23 µm, uptake of vectors by both Kupffer cells 
and liver sinusoidal endothelial cells may attenuate the efficiency of hepatocyte-directed 
gene transfer.  
Most experimental work on the role of liver reticulo-endothelial cells in relation to 
hepatocyte transduction has been performed with adenoviral vectors. These studies support 
the dual role of liver reticulo-endothelial cells in hepatocyte-directed gene transfer. On the 
one hand, the high endocytotic capacity of these cells limits hepatocyte transduction, on the 
other hand, the presence of fenestrae facilitates hepatocyte transduction20. The relevance of 
these observations for other types of vectors and other modes of gene transfer will 
subsequently be discussed.  
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4. In vitro and in vivo transduction by adenoviral vectors 
Efficient hepatocyte transduction by adenoviral vectors requires that two clearly distinct 
conditions are met. First, adenoviral vectors should have a facilitated access to the space of 
Disse via sufficiently large sinusoidal fenestrae. Second, vectors in the space of Disse must 
be able to bind to cellular receptors on hepatocytes for internalisation and transduction. 
Thus, both the anatomical access of vectors to the space of Disse and the potential for 
interaction with hepatocyte receptors in vivo are necessary but not always sufficient for 
hepatocyte transduction in vivo. Before going into the anatomical access of vectors to the 
space of Disse, we will first discuss differences between adenoviral transduction in vitro and 
transduction of hepatocytes in vivo.  
For humans, 51 adenovirus serotypes have been identified, and these serotypes are 
classified into 6 species (A-F). In vitro, uptake of most Ad serotypes belonging to species A, 
C, D, E, and F, is initiated by binding of the adenovirus fiber protein to coxsackie and 
adenovirus receptor (CAR) on the cell surface21, 22. CD46, a complement regulatory protein 
that is ubiquitously expressed in humans23, but only in the testis in mice24, is a cellular 
receptor for group B adenoviruses23. Human species C adenovirus serotype 5 (Ad5) is the 
most common viral vector used in clinical studies worldwide25. In vitro, Ad5 infects cells 
through binding of the fiber to CAR, followed by binding of an arginine-glycine-aspartic 
acid (RGD)-motif on the Ad5 penton base with cellular integrins (mainly v3 and v5) 
which initiates receptor-mediated endocytosis via clathrin coated pits26, 27. However, CAR 
binding ablation28, 29 and v integrin binding ablation29, 30 do not significantly reduce liver 
transduction by adenoviral vectors in vivo. The direct Ad binding to hepatic heparan sulfate 
proteoglycans via the KKTK motif within the fiber shaft domain has been suggested to be 
the major mechanism of hepatocyte transduction in vivo31, 32. However, mutation of the 
KKTK motif in the Ad5 fiber shaft renders the fiber inflexible and prevents internalisation of 
Ad5 though steric hindrance33, 34. In vitro and in vivo infectivity studies of Ad5-based vectors 
possessing long Ad31- (species A) or Ad41- (species F) derived fiber shaft domains that lack 
the KKTK motif, have shown that these vectors transduce hepatocytes with similar 
efficiency compared to Ad5 vectors35, consistent with the absence of a critical role of the 
KKTK motif in hepatocyte transduction.  
An important difference between in vitro transduction and in vivo transduction of liver cells 
after intravenous injection is that adenoviral vectors are in contact with blood proteins. 
Treatment of mice with the vitamin K antagonist warfarin, which inactivates several 
proteins of the coagulation cascade (factor II, factor VII, factor IX, factor X) as well as the 
anticoagulant protein C, abrogates transduction of hepatocytes by adenoviral serotype 5 
vectors8, 36-38. These studies suggested that a coagulation protein or coagulation proteins 
have a bridging function in the entry of liver cells by adenoviral vectors. Only factor X could 
rescue liver transduction in warfarin anticoagulated mice39. Recently, it has been shown that 
the -carboxyglutamic acid domain of factor X binds in a calcium-dependent manner to 
hexon protein in adenovirus serotype 525, 39, 40. Factor X binds at the cup formed by the 
center of each hexon trimer. Serotypes with a high affinity for factor X, such as the species C 
serotypes Ad2 and Ad5, have been shown to efficiently transduce hepatocytes following 
intravenous administration41, 42. In contrast, species B Ad35 and species D Ad26 bind to 
factor X weakly or not at all, and fail to transduce hepatocytes39, 43, 44. More specifically, 
factor X binds to the adenovirus hexon hypervariable regions (HVRs). Liver infection by the 
factor X-Ad5 complex is mediated through a heparin-binding exosite in the factor X serine 
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protease domain. Substitution of HVR5 or HVR7 from Ad5 with sequences from the non-
factor X binding serotype Ad26 substantially lowered factor X binding and liver 
transduction in vivo45. An Ad5 mutant containing an insertion in HVR5 was shown to bind 
factor X in vitro with 10 000-fold reduced affinity compared with unmodified vector and 
failed to deliver the red fluorescent protein transgene in vivo25. Taken together, factor X 
binding to hexon trimer is a necessary prerequisite for hepatocyte transduction in vivo39. 
5. Liver trapping of adenoviral vectors 
Previous studies have shown that different adenoviral serotypes are rapidly sequestered in 
the liver after intravenous delivery, independent of their potential to effectively transduce 
hepatocytes43, 46, 47. Trapping of adenoviral vectors in the liver is comparable between wild-
type mice and mice treated with warfarin, which shows that factor X-facilitated adenoviral 
vector entry into hepatocytes is not required for trapping of vectors in the liver8. 
Demonstration of liver sequestration using whole livers does not make a distinction 
between the presence of vectors extracellularly (in the vascular lumen of the sinusoids or in 
the space of Disse) or intracellularly (in the non-parenchymal liver cells of the parenchymal 
liver cells). Cellular uptake of adenoviral vectors after systemic gene transfer occurs 
predominantly in non-parenchymal liver cells (i.e. mainly liver sinusoidal endothelial cells 
and Kupffer cells)4-7. Kupffer cells may bind adenoviral vectors via multiple mechanisms 
including scavenger receptor-A, complement, and natural antibodies9-11 and this uptake is 
independent of factor X10, 11. Interactions of adenoviral vectors with platelets in blood may 
contribute significantly to sequestration in the reticuloendothelial system of the liver9. 
Nevertheless, the exact mechanisms of adenoviral vector uptake in Kupffer cells have not 
been elucidated. The amount of Ad vector DNA after intravenous administration was nearly 
identical in wild-type mice and scavenger receptor-A deficient mice11 consistent with the 
presence of multiple pathways leading to Kupffer cell sequestration10. 
Recently, Di Paolo et al.11 showed that simultaneous treatment of mice with warfarin and 
clodronate liposomes, that deplete Kupffer cells, results in only a minor reduction of 
sequestration of adenoviral vectors in the liver 1 hour after gene transfer. Transmission 
electron microsopy showed the presence of vectors in the space of Disse, consistent with 
anatomical sequestration of vectors. We suggest that the presence of fenestrae is crucial in 
the liver targeting of adenoviral vectors. In other words, the targeting of adenoviral vectors 
to the liver reflects predominantly or exclusively anatomical targeting. This also implies that 
molecular strategies directed at liver detargeting of adenoviral vectors should take into 
account the existence of anatomical targeting to the liver. 
6. Uptake of gene transfer vectors by reticulo-endothelial cells of the liver 
reduces hepatocyte transduction 
Both Kupffer cells and liver sinusoidal endothelial cells take up the large majority of 
adenoviral vectors after systemic gene transfer7. Uptake of vectors by non-parenchymal liver 
cells (i.e. mainly liver sinusoidal endothelial cells and Kupffer cells) inversely correlates with 
transduction of parenchymal liver cells7. The transgene DNA copy number in the non-
parenchymal liver cells at one hour after transfer in Balb/c mice was nearly 6-fold higher 
than in C57BL/6 mice7. This difference in scavenging of vectors between both strains is a 
major determinant of the approximately 3-fold higher transgene DNA levels in hepatocytes 
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and higher transgene expression levels in C57BL/6 mice compared to Balb/c mice7. Based 
on more refined experiments with isolation of Kupffer cells and liver sinusoidal endothelial 
cells, we showed that the transgene DNA copy number per diploid genome at 1 hour after 
transfer in C57BL/6 mice was 2.9-fold higher in liver sinusoidal endothelial cells than in 
Kupffer cells7. In contrast, the copy number in Kupffer cells was 2.6-fold higher than in liver 
sinusoidal endothelial cells in Balb/c mice. These data indicate that the relative contribution 
of liver sinusoidal endothelial cells and Kupffer cells to adenoviral vector clearance may be 
highly dependent on the specific genetic context. One explanation for this difference of 
uptake of adenoviral vectors by the liver reticulo-endothelial cells of C57BL/6 and Balb/c 
mice may be the differential modulation of the function of these cells by humoral factors 
produced by spleen cells. Indeed, a significantly reduced transgene DNA copy number was 
observed in the liver reticulo-endothelial cells one hour after adenoviral transfer in 
splenectomized Balb/c mice and in Balb/c rag-2-/- mice compared to control Balb/c mice7. 
This was accompanied by a significantly higher transgene DNA copy number in 
hepatocytes of splenectomized Balb/c mice and of Balb/c rag-2-/- mice than in hepatocytes 
of wild-type Balb/c mice7. Splenectomy in Balb/c rag-2-/- mice did not result in an 
incremental effect7. This suggests that humoral factors produced by spleen lymphocytes 
may affect the clearance of adenoviral vectors by liver reticulo-endothelial cells in Balb/c 
mice. In contrast, no such effects on intrahepatic transgene DNA distribution were observed 
in splenectomized C57BL/6 mice and in C57BL/6 rag-1-/- mice, suggesting highly 
heterogeneous effects of humoral factors produced by spleen lymphocytes on liver reticulo-
endothelial cells. 
Further evidence for a major role of liver reticulo-endothelial cells as a determinant of 
hepatocyte transduction comes from experiments with clodronate liposomes. Depletion of 
Kupffer cells and macrophages in the spleen by intravenous administration of clodronate 
liposomes results in significantly increased transgene DNA levels in parenchymal liver cells7 
and in increased transgene expression6, 7, 48, 49. Since liver sinusoidal endothelial cell function 
may be modified by Kupffer cells50, 51, it cannot be excluded that part of the effect of 
clodronate liposomes is due to reduced activation of liver sinusoidal endothelial cells by 
Kupffer cells. Besides clodronate liposomes, pre-administration of polyinosinic acid, a 
scavenger receptor A ligand, before gene transfer has been shown to prevent sequestration 
of adenoviral vectors in Kupffer cells and to enhance parenchymal liver cell transduction52. 
Transient saturation of the reticulo-endothelial system with phosphatidylcholine liposomes 
or with Intralipid® also reduces uptake of vectors in the non-parenchymal liver cells and 
augments hepatocyte transduction7. Taken together, various interventions that result in 
reduced uptake of adenoviral vectors in liver reticulo-endothelial cells consistently enhance 
hepatocyte transduction.  
7. Liver sinusoidal endothelial fenestrae 
Liver sinusoids are highly specialized capillaries with two critical features: the thin 
endothelium contains open fenestrae, whereas a basal lamina is lacking53. Fenestrae are 
clustered in sieve plates and provide an open pathway between the sinusoidal lumen and 
the space of Disse, in which numerous microvilli from parenchymal liver cells protrude53, 54. 
Sinusoidal fenestrae have no diaphragm and visualisation requires perfusion fixation with 
glutaraldehyde. Scanning electron microscopy analysis has shown that sinusoidal fenestrae 
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comprise 6–8% of the sinusoidal surface55. Compared to the centrilobular area, the diameter 
of fenestrae is larger but the frequency of fenestrae is lower in the periportal area55, 56.  
The open communication between the sinusoidal lumen and the space of Disse through 
fenestrae represents a unique route that provides direct access for gene transfer vectors to 
the surface of hepatocytes. However, fenestrae act as a sieve and will mechanically restrict 
the transport of gene transfer vectors according to their size. Thus, two parameters must be 
taken into account when considering the access of gene transfer vectors to hepatocytes 
namely the diameter of both fenestrae and gene transfer vectors. 
8. Species variation of the average diameter of fenestrae 
Fenestrae generally measure between 100 nm and 200 nm and significant species differences 
in their size exist53-55. However, the interpretation of the existing literature on species 
variations of the size of sinusoidal fenestrae is hampered by differences in preparatory 
methods applied by different investigators. Standardised protocols within one group of 
investigators are therefore a conditio sine qua non for reliable species and strain comparisons. 
A direct comparative study of the diameter of sinusoidal fenestrae in five species using 
scanning electron microscopy was performed by Higashi et al.57. The average diameter of 
sinusoidal endothelial fenestrae in this study was 45 nm in cows, 52 nm in sheep, 66 nm in 
guinea pigs, 82 nm in pigs, and 131 nm in dogs57. However, these results are based on 
scanning electron microscopy preparations and are therefore subject to a shrinkage effect in 
the order of 30% caused by dehydration and drying of the tissue58. Accurate measurements 
of fenestrae can only be obtained by gradually replacing cellular water by plastic during 
preparation for transmission electron microscopy59. Previous studies have shown that this 
method of preparation leads to accurate measurements of cellular details, such as fenestrae. 
Visualisation of fenestrae in transmission electron microscopy sections requires that 
endothelial cells and their sieve plates are cut tangentially so that fenestrae become visible 
as holes. Using this technology and standardized protocols, it has previously been shown 
that the average diameter of fenestrae is significantly larger in Sprague Dawley rats (150 nm 
in the pericentral area and 175 nm in the periportal area)55 and C57BL/6 mice (141 nm)60 
than in New Zealand White rabbits (103 nm)60, Fauve de Bourgogne rabbits (105 nm)61, and 
humans with a healthy liver (107 nm)62. The diameter in Dutch Belt rabbits was intermediate 
(124 nm)61. Taken together, this species comparison demonstrates that the diameter of 
fenestrae in humans is similar to New Zealand White rabbits and significantly smaller 
compared to mice and rats, two species that are most frequently used in gene transfer 
studies. The occurrence of major shrinkage effects in scanning electron microscopy samples 
is indicated by the significantly lower diameters reported for New Zealand White rabbits (49 
nm)63 and Sprague Dawley rats (89 nm)63 as compared to diameters obtained in 
transmission electron microscopy studies55, 60. Transmission electron microscopy studies 
consistently show that the interindividual variation of the average diameter of fenestrae 
within the same species or strain is low, as indicated by coefficients of variation between 3-
8%. In contrast, as will be discussed in the next paragraph, the intraindividual variation of 
diameters of fenestrae is high. 
9. Intraindividual variation of the diameter of fenestrae 
The intraindividual variation of the diameter of fenestrae is an important parameter that 
may complicate investigations on the relation between the diameter of fenestrae and gene 
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transfer efficiency to hepatocytes. The distribution of the diameters of fenestrae within one 
individual or within one animal follows a Gaussian function with some skewing to the 
right20. 
Two opposing processes will determine the entrance of vectors into the space of Disse: on 
the one hand passage through sinusoidal fenestrae and on the other hand endocytosis by 
Kupffer cells and endothelial cells. Species and strain differences in transendothelial passage 
will be determined by intrinsic differences of the function of liver reticulo-endothelial cells 
(e.g. C57BL/6 versus Balb/c mice) as well as the rate passage of vectors through fenestrae. 
Based on these considerations, one can predict that the ratio of transgene DNA copy number 
in parenchymal liver cells versus the copy number in sinusoidal liver cells will correlate 
positively with the diameter of fenestrae. After reviewing data on the diameters of different 
gene transfer vectors, we will present several lines of experimental evidence that support 
the critical role of the diameter of fenestrae in hepatocyte transduction. 
10. Diameters of gene transfer vectors 
To put the importance of the size of fenestrae for hepatocyte-directed gene transfer into 
perspective, accurate knowledge of the diameter of gene transfer vectors is required. To 
avoid bias in the measurement of the diameter of adenoviral vectors, we previously vitrified 
a sample of adenoviral vectors using VitrobotTM technology and determined the diameter by 
cryo-electron microscopy60. Adenoviral serotype 5 virions were shown to have a diameter of 
93 nm with protruding fibers of 30 nm60. Using the same imaging techniques, the diameter 
of a vesicular stomatitis virus-G pseudotyped human immunodeficiency virus-1 derived 
lentiviral vector was found to be 150 nm60. Adeno-associated viral serotype 2 vectors have 
an average diameter of 22 nm64. Herpes simplex virions have been reported to be as large as 
180 nm65. The diameter of liposomes used for non-viral gene transfer varies between 50 nm 
and 1000 nm and is highly dependent on production parameters66, 67. 
11. Experimental evidence for a critical role of sinusoidal fenestrae in 
hepatocyte transduction following adenoviral gene transfer 
Based on our prior studies in different strains of rabbits and in different species60-62, the 
correlation coefficient between the average diameter of sinusoidal fenestrae in these 
different strains and species and human apo A-I expression at day 7 after transfer with an 
adenoviral vector containing a hepatocyte-specific expression cassette was found to be 0.94 
(p<0.01). This strongly suggests that the diameter of sinusoidal fenestrae is an important 
determinant of gene transfer efficiency to hepatocytes.  
To demonstrate that the difference of human apo A-I plasma levels reflects differences of 
transgene DNA levels in parenchymal liver cells, we isolated parenchymal and non-
parenchymal liver cells at day 3 after transfer in C57BL/6 mice and New Zealand White 
rabbits. Transgene DNA levels in parenchymal liver cells were much higher in C57BL/6 
mice than in New Zealand White rabbits whereas the reverse pattern was observed in non-
parenchymal liver cells60. Considering the small average diameter of fenestrae in New 
Zealand White rabbits (103 nm), it appears that the sinusoidal wall constitutes a histological 
barrier for adenoviral vectors in this species leading to increased uptake by liver reticulo-
endothelial cells. In contrast, the larger fenestrae in C57BL/6 mice (141 nm) facilitate access 
to hepatocytes, leading to increased uptake into hepatocytes and to reduced scavenging by 
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Kupffer cell and liver sinusoidal endothelial cells. In other words, the size of fenestrae 
determines the distribution of vectors between sinusoidal and parenchymal liver cells. 
Although the relation between the diameter of sinusoidal fenestrae and transgene 
expression after adenoviral gene transfer may be confounded by substantial differences in 
genetic background, we showed that interventions that increase the diameter of fenestrae 
result in New Zealand White rabbits significantly increased transgene expression60, 61. These 
two intervention studies support the view that the correlation between the diameter of 
fenestrae and transgene expression after adenoviral transfer reflects a causal relationship. 
Based on the high degree of similarity of the distribution of the diameter of fenestrae 
between humans and New Zealand White rabbits20, 68, one would predict a low efficiency of 
gene transfer into hepatocytes after adenoviral transfer in humans. In the ornithine 
transcarbamylase deficiency trial, low levels of gene transfer in hepatocytes were indeed 
observed69. The authors concluded that the level of transgene expression was lower than 
what would have been predicted based on preclinical animal models69. Although 
histological alterations of the livers in patients with partial ornithine transcarbamylase 
deficiency may have contributed to low hepatocyte transduction, we speculate that a much 
smaller size of fenestrae in humans compared to mice and rats is likely the most critical 
factor in the observed species difference of hepatocyte transduction. On the other hand, the 
small diameter of fenestrae in humans may be beneficial for the efficacy of molecular 
strategies directed at liver detargeting of adenoviral vectors since anatomical targeting to 
the liver will be limited. 
Recently, Brunetti-Pierri et al.70 developed a minimally invasive procedure that significantly 
improves the efficiency of hepatocyte-directed transfer in nonhuman primates. A balloon 
occlusion catheter was percutaneously positioned in the inferior vena cava to occlude hepatic 
venous outflow70. Gene transfer of gutted vectors was performed via a percutaneously 
placed hepatic artery catheter with an infusion time of 7.5 minutes or 15 minutes. This 
procedure resulted in approximately 10-fold higher transgene expression levels compared to 
systemic gene transfer. Increased intrahepatic pressure following occlusion of hepatic 
outflow of the liver may increase the diameter of fenestrae, similar as observed following 
hydrodynamic injections in mice71, and this may contribute to the beneficial effects of this 
procedure in monkeys. 
12. Potential relevance of sinusoidal fenestrae for other modes of 
hepatocyte-directed gene transfer 
Based on the data obtained with adenoviral vectors, it is likely that the large diameter of 
lentiviral vectors is an important limitation for hepatocyte-directed gene transfer and may 
restrict passage of vectors even in mice and rats. Indeed, gene transfer efficiency in mice and 
rats is low after in vivo lentiviral gene transfer72-75. Although other factors like technological 
challenges to obtain high titer vector stocks may play a role, it is likely that the large 
diameter of lentiviral vectors is a limitation for hepatocyte-directed gene transfer. Since this 
anatomical limitation does not exist for adeno-associated viral vectors, gene transfer 
efficiency into hepatocytes with this type of vectors will be solely dependent on cellular and 
molecular determinants of hepatocyte transduction.  
Fenestrae may also play a role in naked DNA transfer. Liu et al.76 showed that the murine 
liver can rapidly extract up to 25 µg of plasmid DNA from the blood during a single pass 
after simple intravenous injection. Moreover, this study showed that naked DNA is 
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primarily taken up by the liver endothelial cells, but not by Kupffer cells, and that 
transfection of hepatocytes can be improved by mechanical massage of the liver, which 
increases the size of liver sinusoidal fenestrae76. Substantial amounts of plasmid DNA are 
degraded by nucleases in the blood following simple intravenous injection, which can be 
overcome by hydrodynamic gene transfer. It has also been proposed that fenestrae play a 
role in the transport of naked DNA into hepatocytes during hydrodynamic gene transfer71. 
Although the exact mechanism of hepatocyte transfection following hydrodynamic gene 
transfer remains to be elucidated, a general consensus is that the injected volume induces 
right heart volume overload. This results in a retrograde flow through the vena cava and in 
particular in a retrograde flow into the hepatic veins. As a result, intrahepatic pressure 
increases and the DNA containing solution is forced out of the hepatic sinusoids into the 
parenchymal liver cells. Following systemic hydrodynamic gene transfer in mice and rats, 
the majority of the injected DNA (i.e. >90%) can be retrieved in the liver77. In addition, 
microscopic analysis has indicated that transfected hepatocytes are predominantly located 
in the pericentral region78. This predilection may be explained by the fact that sinusoids are 
wider and straighter and contain more fenestrae per unit of surface in the pericentral area 
than in the periportal area56, 77.  
13. Sinusoidal fenestrae and hepatocyte transduction in diseased livers 
The unique morphological features of liver sinusoidal endothelial cells may change in 
pathological conditions. Liver fibrosis and cirrhosis lead to a decreased number of 
fenestrae79 and capillarization and perisinusoidal fibrosis leads to the development of a 
basal lamina, found to be absent in normal sinusoids. A significant reduction in the number 
of fenestrae and porosity of the sinusoidal endothelial cells was observed in alcoholic liver 
disease without cirrhosis80. In a comparative study, decreased transduction by adenoviral 
vectors has been observed in cirrhotic rat livers compared to normal livers81. Furthermore, 
hydrodynamic gene transfer was significantly less efficient in rats with a fibrotic liver 
compared to rats with a healthy liver82. Sinusoidal capillarization also occurs in 
hepatocellular carcinoma83, 84. This may constitute a major obstacle for efficient gene therapy 
for liver cancers. 
14. General perspective 
Preclinical viral and non-viral gene transfer studies should consider scavenging of vectors 
by liver reticulo-endothelial cells and as well as the diameter of sinusoidal fenestrae as 
important determinants of gene transfer efficiency into hepatocytes. Although the diameter 
of fenestrae may be modulated to some extent, there is currently no safe pharmacological 
intervention that results in a significant enlargement of fenestrae. The small diameter of 
fenestrae in humans and alterations of liver sinusoidal endothelial cells in liver disease may 
constitute a significant and potentially insurmountable obstacle for efficient gene transfer 
into hepatocytes with several vectors. Both anatomical access of vectors to the space of Disse 
on the one hand and the potential of vectors for interaction with hepatocyte receptors in vivo 
on the other hand are necessary for efficient hepatocyte transduction in vivo. A model on 
hepatocyte transduction should therefore take into account that both an anatomical 
prerequisite and a molecular prerequisite have to be met. 
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15. Innate and adaptive immune responses: an introductory perspective 
The use of non-viral gene therapy vectors, including naked DNA and liposomes, results in 
very low to suboptimal expression levels with the possible exception of hydrodynamic gene 
transfer85-87. However, this latter method is only successful in mice and rats and attempts for 
implementation of this methodology in larger species have resulted in very low gene 
transfer efficiencies88-90. Therefore, our strategic point of view is that only viral vectors 
constitute sufficiently potent gene delivery platforms to treat genetic and acquired diseases. 
Although viral vectors are non-replicative in contrast to wild-type viruses, the immune 
system is efficient to fight off what it perceives as invading pathogens. Innate immune 
responses are initiated by recognition of pathogen-associated molecular patters by pattern 
recognition receptors like Toll-like receptors on the surface of professional antigen 
presenting cells. Subsequent production of inflammatory cytokines stimulates maturation of 
antigen presenting cells, enhances their endocytic activity, and upregulates expression of 
molecules required for antigen processing and presentation and for costimulation. Viral 
capsid proteins not only elicit innate immunity but are also viable targets for host adaptive 
immune responses that do not necessarily require de novo viral gene expression. Adaptive 
immune responses against vector-derived antigens may reduce the efficacy of in vivo gene 
transfer and may prevent readministration. Furthermore, many vectors are derived from 
parent viruses that humans have encountered through natural infection, resulting in pre-
existing antibodies and possibly in memory responses against vector antigens. Taken 
together, adaptive immune responses represent one the most challenging remaining hurdles 
for the development of viral hepatocyte-directed gene transfer strategies with a sufficient 
therapeutic index. Besides the issue of adaptive immune responses against the vector and 
the potential problem of pre-existing immunity, immune responses against the transgene 
product also constitute a hurdle. 
16. Innate immune responses after viral gene transfer 
Adenoviral vectors efficiently transduce liver cells after systemic gene transfer and 
expression levels are generally significantly higher as compared to non-viral, adeno-
associated viral, and lentiviral transfer. However, recognition of molecular patterns on 
adenoviral capsids by pattern recognition receptors on macrophages and dendritic cells 
triggers innate immune responses and induces the production of several cytokines and 
chemokines6, 91-96. Severe activation of the innate immune system, as observed in patients 
with systemic microbial infections, severe trauma, or after major surgery, may lead to a 
systemic inflammatory response syndrome, or even to multiple system organ failure and 
shock. The development of systemic inflammatory response syndrome and multiple system 
organ failure after adenoviral transfer is dose and species dependent69, 94, 97. Schnell et al.94 
demonstrated significant species variation in innate immune responses after adenoviral 
gene transfer. Mice did not develop clinical symptoms of systemic inflammatory response 
syndrome at any dose of vector whereas rhesus monkeys developed liver necrosis and 
coagulopathy at a dose of 1013 particles/kg of an E1-deleted vector94. The sensitivity of 
humans to adverse effects of innate immune responses after adenoviral transfer is 
significantly higher than in rhesus monkeys as significant side-effects have been observed at 
doses of 6 × 1011 particles/kg or even lower69.  
Interleukin (IL)-6 is not only produced by macrophages and T cells but also by liver 
sinusoidal endothelial cells98 and possibly by spleen sinusoidal endothelial cells. 
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Notwithstanding the fact that Kupffer cells are by large the most numerous population of 
resident macrophages in the body, we have shown that the predominant source of IL-6 after 
adenoviral transfer in C57BL/6 mice is the spleen and not the liver or lungs99. This finding is 
based both on gene transfer experiments in splenectomized mice as well as on quantification 
of IL-6 mRNA levels in different organs following adenoviral transfer99.  
Innate immune responses following adenoviral transfer are dependent on both Toll like 
receptor (TLR) 2 and TLR9100. TLR2 and TLR9 are expressed in Kupffer cells but also in the 
spleen101-103 as well as in liver sinusoidal endothelial cells102.  
Depletion of tissue macrophages and dendritic cell subpopulations in liver and spleen by 
the administration of liposomes encapsulating dichloromethylene-biphosphonate results in 
reduced plasma levels of IL-6, IL-12, and tumor necrosis factor (TNF)-93. However, this 
cytotoxic strategy is unlikely to be applicable in humans. Conjugation of adenoviral vectors 
with activated monomethoxypolyethylene glycols (MPEG) has been shown to reduce IL-6 
plasma levels after adenoviral transfer99, 104. In addition, we have shown that the 
combination of PEGylation of adenoviral vectors and administration of methylprednisolone 
completely suppresses elevations of IL-6 levels after transfer with E1E3E4-deleted 
adenoviral vectors at a dose of 4 x 1012 particles/kg99. This combined strategy also inhibits 
chemokine expression in the liver, abrogates neutrophil infiltration and T-lymphocyte 
infiltration in the liver, and reduces elevations of serum transaminases in the early phase 
after adenoviral transfer99.  
Since dose reduction represents an additional means to attenuate innate immune responses 
against adenoviral vectors, strategies to enhance the efficiency of hepatocyte transduction 
are required to obtain therapeutic expression levels at lower doses. Brunetti-Pierri et al.70 
developed a minimally invasive procedure that significantly improves the therapeutic index 
of hepatocyte-directed transfer in nonhuman primates. A balloon occlusion catheter was 
percutaneously positioned in the inferior vena cava to occlude hepatic venous outflow70. 
Gene transfer of gutted vectors was performed via a percutaneously placed hepatic artery 
catheter with an infusion time of 7.5 minutes or 15 minutes. This procedure resulted in 
approximately 10-fold higher transgene expression levels compared to systemic gene 
transfer. At vector doses of 1 x 1010 or 3 x 1010 particles/kg, IL-6 levels were consistently 
below 100 pg/ml70.  
In contrast to adenoviral gene transfer, adeno-associated viral gene transfer induces very 
weak or absent innate immune responses to viral capsids both in mice95 and monkeys105. 
Serum levels of five major inflammatory cytokines (TNF-, interferon-, IL-6, IL-10, and IL-
12) were not elevated in macaques after gene transfer with vectors based on adeno-
associated virus serotypes 2, 7, and 8105. These data suggest that very weak or absent innate 
immune responses to adeno-associated viral capsids may be a general observation in 
different species. Nevertheless, some level of innate immune activation occurs even with 
adeno-associated viral vectors106. 
17. Adaptive immune responses after hepatocyte-directed gene transfer 
T helper cell activation is complex. Besides signalling via pattern recognition receptors 
(signal 0), T cell activation requires interaction of the T cell receptor CD3 complex with 
antigen presented in Major Histocompatibility Complex II (MHCII) (signal 1), engagement 
of costimulatory molecules such as CD80/86 on antigen presenting cells with CD28 on T 
cells or CD40 on antigen presenting cells with CD40 ligand on T cells (signal 2), and a 
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specific cytokine milieu (signal 3) that primes a T helper 1 (Th1) or a T helper 2 (Th2) 
response. Immunological tolerance is a state in which the immune system is not capable to 
activate the appropriate cellular or humoral immune responses following antigen exposure. 
In absence of signal 1, naive T cells are never primed, resulting in immunological ignorance. 
In the absence of adequate costimulation (signal 2), immunological tolerance is based on 
anergy/deletion: antigen-specific T cells are primed but are functionally deficient with 
regard to proliferation and cytokine production. In the absence of signal 3, regulatory T cells 
(Tregs) may develop. Tregs actively suppress adaptive immune effectors. Taken together, 
there are multiple requirements for adequate priming of T cells, which offers perspectives 
for induction of antigen specific tolerance. 
Immune responses in mice are highly strain dependent. C57BL/6 mice preferentially 
develop a predominantly Th1-type immune response whereas Balb/c mice develop a Th2-
type immune response107. Nevertheless, we have shown that cellular immune responses 
against adenoviral epitopes do not play a role in transgene DNA kinetics in C57BL/6 
mice108. This implies that, in the absence of an adaptive immune response against the 
transgene product, non-immune mechanisms are responsible for the decrease of transgene 
DNA over time. Whether this is also the case in Balb/c mice, is unknown. Taken together, 
episomal stability of non-integrated transgenes is an important issue. This is further 
highlighted by our observations that the persistence of transgene DNA is dependent on the 
expression cassette design109-111. 
Treatment of genetic diseases by gene replacement therapy is hampered by adaptive 
immune responses against the transgene product. The risk of antibody formation against the 
transgene product may be limited in the specific setting of hepatocyte-directed gene 
transfer112-114 and specifically by restricting transgene expression to hepatocytes by use of 
hepatocyte-specific expression cassettes115, 116.  
We consistently observed the absence of antibodies against human apolipoprotein (apo) A-I 
in all investigated murine strains after gene transfer with vectors containing a hepatocyte-
specific expression cassette110, 115. This absence of a humoral immune response has also been 
observed after gene transfer with the same vector in rats117. However, this observation 
cannot be robustly extrapolated to other species. In contrast to findings in mice and rats, we 
have previously observed a vigorous humoral immune response against human apo A-I in 
three different rabbit strains following transfer with AdA-I leading to the disappearance of 
detectable human apo A-I levels within 14 days61.  
18. Development of expression cassettes for hepatocyte-directed gene 
transfer 
The development of potent hepatocyte-specific expression cassettes for gene transfer offers 
several advantages. First, a therapeutic effect may be obtained at a lower vector dose, thus 
providing a means to improve the therapeutic index of vectors. Second, hepatocyte-specific 
expression cassettes represent a very efficient way to restrict transgene expression to 
hepatocytes, i.e. transcriptional targeting108, 111, 115. In contrast, targeting vectors to 
hepatocytes is significantly more difficult to realise. Third, hepatocyte-specific expression 
cassettes may lead to immunological unresponsiveness to an immunogenic transgene 
product via immunological ignorance or immunological tolerance110, 114, 115, 118, 119.  
Optimalisation of transgene expression may be achieved by modulating all levels of 
expression including transcription, post-transcriptional modification of RNA, RNA export, 
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RNA stability, and translation. Expression cassettes for hepatocyte-directed transfer have 
been improved by using new promoter-enhancer combinations109, 111, 119-123, inclusion of 
introns109, 124-127, and inclusion of additional transcriptional sequences like scaffold matrix 
attachment regions (SMAR) and hepatic control regions (HCR)126, 128-132. In a series of 
studies87, 108-111, 115, 133, we have performed a direct in vivo comparison of nearly 50 different 
expression cassettes in the context of gene transfer with E1-deleted or E1E3E4-deleted 
adenoviral vectors using human apo A-I plasma levels in C57BL/6 mice as end-point. These 
studies represent a continuous improvement of expression cassettes. The conclusion of these 
investigations is that the DC172 promoter, consisting of an 890 bp human 1-antitrypsin 
promoter and two copies of the 160 bp 1-microglobulin enhancer, upstream of the genomic 
human apo A-I sequence and 2 copies of the HCR-1, represents at present the most potent 
expression cassette. After gene transfer with a moderate dose (5 x 1010 particles) of an 
E1E3E4-deleted vector containing this expression cassette, human apo A-I levels in C57BL/6 
mice were more than 3-fold higher than physiological plasma levels in humans87. In 
addition, hydrodynamic gene transfer of minicircles containing this expression cassette 
resulted in sustained plasma levels in C57BL/6 mice that were equivalent to physiological 
levels in humans87. 
19. General conclusion 
The limited external validity of experimental gene transfer studies with regard to several of 
the parameters discussed in this review provides a framework to understand why clinical 
translation of hepatocyte-directed gene transfer is such a major challenge. It is inherent to 
gene transfer technologies that a wide variety of biological processes affect the ultimate 
outcome of these interventions. This number of biological determinants is significantly 
higher compared to classical pharmaceutical therapies or to protein infusion therapies. 
Species or strain variation of any of these multiple determinants of the outcome of 
hepatocyte-directed gene transfer hinders the process of clinical translation. Considering the 
relative small size of fenestrae in humans, one important parameter that should be 
considered is the diameter of gene transfer vectors. A progressive increase of fundamental 
insights into species variations of determinants of the success of hepatocyte-directed gene 
transfer may provide a solid base for technological advances that may result in more robust 
technologies and finally in clinical translation. At the present time, it is our view that 
hepatocyte-directed adeno-associated viral gene transfer has the greatest potential for 
clinical translation. This view is based on two fundamental properties of these vectors: (1) 
their size is small enough to pass through human fenestrae that are characterised by a much 
smaller diameter than those of rodents and (2) innate immune responses are very weak after 
adeno-associated viral gene transfer. Taken together, the current review contains multiple 
elements that are a foundation to make stable progress in this field and that provide a 
realistic perspective on the future of hepatocyte-directed gene transfer. 
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